Cholestyramine alleviates bone and muscle loss in irritable bowel syndrome via regulating bile acid metabolism

Abstract

Irritable bowel syndrome (IBS) is a widespread gastrointestinal disorder known for its multifaceted pathogenesis and varied extraintestinal manifestations, yet its implications for bone and muscle health are underexplored. Recent studies suggest a link between IBS and musculoskeletal disorders, but a comprehensive understanding remains elusive, especially concerning the role of bile acids (BAs) in this context. This study aimed to elucidate the potential contribution of IBS to bone and muscle deterioration via alterations in gut microbiota and BA profiles, hypothesizing that cholestyramine could counteract these adverse effects. We employed a mouse model to characterize IBS and analysed its impact on bone and muscle health. Our results revealed that IBS promotes bone and muscle loss, accompanied by microbial dysbiosis and elevated BAs. Administering cholestyramine significantly mitigated these effects, highlighting its therapeutic potential. This research not only confirms the critical role of BAs and gut microbiota in IBS-associated bone and muscle loss but also demonstrates the efficacy of cholestyramine in ameliorating these conditions, thereby contributing significantly to the field’s understanding and offering a promising avenue for treatment.

References

[1] SahaL. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-base. medicine. World J Gastroenterol. 2014;20(22):6759-6773.

[2] EndoY, ShojiT, FukudoS. Epidemiology of irritable bowel syndrome. Ann Gastroenterol. 2015;28(2):158-159.

[3] WilkinsonJM, GillMC. Irritable bowel syndrome: questions and answers for effective care. Am Fam Physician. 2021;103(12):727-736.

[4] YenCM, MuoCH, LinMC, Chang SN, ChangYJ, KaoCH. A nationwide population cohort study: irritable bowel syndrome is a risk factor of osteoporosis. Eur J Intern Med. 2014;25(1):87-91.

[5] LeeSY, HwangHR, YiYH, et al. Association between irritable bowel syndrome and risk of osteoporosis in Korean premenopausal women. Med Princ Pract. 2021;30(6):527-534.

[6] KirkB, ZankerJ, DuqueG. Osteosarcopenia: epidemiology, diagnosis, and treatment-fact. and numbers. J Cachexia Sarcopenia. 2020;11(3):609-618.

[7] BarkhodariA, LeeKE, ShenM, Shen B, YaoQ. Inflammatory bowel disease: focus on enteropathic arthritis and therapy. Rheumatol Immunol Res. 2022;3(2):69-76.

[8] AshrafiM, KuhnKA, WeismanMH. The arthritis connection to inflammatory bowel disease (IBD): why has it taken so long to understand it? RMD Open. 2021;7(1):e001558.

[9] HouJJ, WangX, WangYM, Wang BM. Interplay between gut microbiota and bile acids in diarrhoea-predominant irritable bowel syndrome: a review. Crit rev Microbiol. 2022;48(6):696-713.

[10] JiaW, XieG, JiaW. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15(2):111-128.

[11] MinYW, RezaieA, PimentelM. Bile acid and gut microbiota in irritable bowel syndrome. J Neurogastroenterol Motil. 2022;28(4):549-561.

[12] ZhaoL, YangW, ChenY, et al. A clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome. J Clin Invest. 2020;130(1):438-450.

[13] Odunsi-ShiyanbadeST, Camilleri M, McKinzieS, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol. 2010;8(2):159-165.

[14] BarkunAN, LoveJ, GouldM, Pluta H, SteinhartH. Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment. Can J Gastroenterol. 2013;27(11):653-659.

[15] Ruiz-GaspàS, Guañabens N, JuradoS, et al. Bilirubin and bile acids in osteocytes and bone tissue. Potential role in the cholestatic-induced osteoporosis. Liver Int. 2020;40(11):2767-2775.

[16] AoiW, InoueR, MizushimaK, et al. Exercise-acclimated microbiota improves skeletal muscle metabolism via circulating bile acid deconjugation. iScience. 2023;26(3):106251.

[17] JinX, HuY, LinT, et al. Selenium-enriched Bifidobacterium longum DD98 relieves irritable bowel syndrome induced by chronic unpredictable mild stress in mice. Food Funct. 2023;14(11):5355-5374.

[18] LiX, LiuQ, YuJ, et al. Costunolide ameliorates intestinal dysfunction and depressive behaviour in mice with stress-induced irritable bowel syndrome via colonic mast cell activation and central 5-hydroxytryptamine metabolism. Food Funct. 2021;12(9):4142-4151.

[19] AntoniukS, BijataM, PonimaskinE, Wlodarczyk J. Chronic unpredictable mild stress for modeling depression in rodents: meta-analysis of model reliability. Neurosci Biobehav Rev. 2019;99:101-116.

[20] O’MahonySM, Tramullas M, FitzgeraldP, CryanJF. Rodent models of colorectal distension. Curr Protoc Neurosci. 2012;61(1):9.40.

[21] Al-ChaerED, Kawasaki M, PasrichaPJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology. 2000;119(5):1276-1285.

[22] ShaidullovIF, Sorokina DM, SitdikovFG, HermannA, Abdulkhakov SR, SitdikovaGF. Short chain fatty acids and colon motility in a mouse model of irritable bowel syndrome. BMC Gastroenterol. 2021;21(1):37.

[23] WeiW, WangHF, ZhangY, Zhang YL, NiuBY, YaoSK. Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome. World J Gastroenterol. 2020;26(45):7153-7172.

[24] GielenE, DupontJ, DejaegerM, Laurent MR. Sarcopenia, osteoporosis and frailty. Metabolism. 2023;145:155638.

[25] PolitoA, Barnaba L, CiarapicaD, AzziniE. Osteosarcopenia: a narrative review on clinical studies. Int J Mol Sci. 2022;23(10):5591.

[26] InoueT, MaedaK, NaganoA, et al. Related factors and clinical outcomes of Osteosarcopenia: a narrative review. Nutrients. 2021;13(2):291.

[27] WongtrakulW, Charoenngam N, UngprasertP. The association between irritable bowel syndrome and osteoporosis: a systematic review and meta-analysis. Osteoporosis Int. 2020;31(6):1049-1057.

[28] SmoljanI, DetelD, BuljevicS, Erjavec I, MarićI. Therapeutic potential of BMP7 in the treatment of osteoporosis caused by the interaction between inflammation and corticosteroids in inflammatory bowel disease. Biomedicines. 2023;11(8):2161.

[29] GuoJ, WangF, HuY, et al. Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases. Cell Rep Med. 2023;4(1):100881.

[30] ZaissMM, JonesRM, SchettG, Pacifici R. The gut-bone axis: how bacterial metabolites bridge the distance. J Clin Invest. 2019;129(8):3018-3028.

[31] TicinesiA, Lauretani F, MilaniC, et al. Aging gut microbiota at the cross-road between nutrition, physical frailty, and sarcopenia: is there a gut–muscle Axis? Nutrients. 2017;9(12):1303.

[32] RaoAS, WongBS, CamilleriM, et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. Gastroenterology. 2010;139(5):1549-1558.1551–1558, 1558.e1.

[33] PelemanC, Camilleri M, BusciglioI, BurtonD, DonatoL, ZinsmeisterAR. Colonic transit and bile acid synthesis or excretion in patients with irritable bowel syndrome-diarrhea without bile acid malabsorption. Clin Gastroenterol Hepatol. 2017;15(5):720-727.

[34] SchroederBO, Bäckhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat med. 2016;22(10):1079-1089.

[35] SugiyamaY, MoriY, NaraM, et al. Gut bacterial aromatic amine production: aromatic amino acid decarboxylase and its effects on peripheral serotonin production. Gut Microbes. 2022;14(1):2128605.

[36] DengX, XiaoL, LuoM, XieP, XiongL. Intestinal crosstalk between bile acids and microbiota in irritable bowel syndrome. J Gastroenterol Hepatol. 2023;38(7):1072-1082.

[37] LongSL, GahanC, JoyceSA. Interactions between gut bacteria and bile in health and disease. Mol Aspects Med. 2017;56:54-65.

[38] JonesBV, BegleyM, HillC, Gahan CG, MarchesiJR. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci USA. 2008;105(36):13580-13585.

[39] VitalM, RudT, RathS, Pieper DH, SchlüterD. Diversity of bacteria exhibiting bile acid-inducible 7α-dehydroxylation genes in the human gut. COMPUT STRUCT BIOTEC. 2019;17:1016-1019.

[40] WangC, ZhuC, ShaoL, Ye J, ShenY, RenY. Role of bile acids in Dysbiosis and treatment of nonalcoholic fatty liver disease. Mediators Inflamm. 2019;2019:7659509.

[41] AbrigoJ, Gonzalez F, AguirreF, et al. Cholic acid and deoxycholic acid induce skeletal muscle atrophy through a mechanism dependent on TGR5 receptor. J Cell Physiol. 2021;236(1):260-272.

[42] ChoSW, AnJH, ParkH, et al. Positive regulation of osteogenesis by bile acid through FXR. J Bone Miner Res. 2013;28(10):2109-2121.

[43] ZhaoYX, SongYW, ZhangL, et al. Association between bile acid metabolism and bone mineral density in postmenopausal women. Clinics. 2020;75:e1486.

[44] YangS, LiH, GuY, et al. The association between total bile acid and bone mineral density among patients with type 2 diabetes. Front Endocrinol. 2023;14:1153205.

[45] StürznickelJ, Behler-Janbeck F, BaranowskyA, et al. Increased concentrations of conjugated bile acids are associated with osteoporosis in PSC patients. Sci Rep. 2022;12(1):16491.

RIGHTS & PERMISSIONS

2024 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.